{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:59:09Z","timestamp":1794470349357,"version":"4.9.1"},"reference-count":64,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2019,10,12]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>A major barrier to improving childhood cancer survival is the perception that paediatric oncology services are too costly for low-income and middle-income country (LMIC) health systems. We conducted a systematic review to synthesise existing evidence on the costs and cost-effectiveness of treating childhood cancers in LMICs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched multiple databases from their inception to March 2019. All studies reporting costs or cost-effectiveness of treating any childhood cancer in an LMIC were included. We appraised included articles using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. Where possible, we extracted or calculated the cost per disability-adjusted life year (DALY) averted using reported survival and country-specific life expectancy. Cost\/DALY averted was compared with per capita gross domestic product (GDP) as per WHO-Choosing Interventions that are Cost-Effective guidelines to determine cost-effectiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 2802 studies identified, 30 met inclusion criteria. Studies represented 22 countries and nine different malignancies. The most commonly studied cancers were acute lymphoblastic leukaemia (n=10), Burkitt lymphoma (n=4) and Wilms tumour (n=3). The median CHEERS checklist score was 18 of 24. Many studies omitted key cost inputs. Notably, only 11 studies included healthcare worker salaries. Cost\/DALY averted was extracted or calculated for 12 studies and ranged from US$22 to US$4475, although the lower-end costs were primarily from studies that omitted key cost components. In all 12, cost\/DALY averted through treatment was substantially less than country per capita GDP, and therefore considered very cost-effective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Many included studies did not account for key cost inputs, thus underestimating true treatment costs. Costs\/DALY averted were nonetheless substantially lower than per capita GDP, suggesting that even if all relevant inputs are included, LMIC childhood cancer treatment is consistently very cost-effective. While additional rigorous economic evaluations are required, our results can inform the development of LMIC national childhood cancer strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2019-001825","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T06:46:41Z","timestamp":1572590801000},"page":"e001825","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review"],"prefix":"10.1136","volume":"4","author":[{"given":"Alastair","family":"Fung","sequence":"first","affiliation":[{"name":"Pediatrics and Child Health, Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Horton","sequence":"additional","affiliation":[{"name":"School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda","family":"Zabih","sequence":"additional","affiliation":[{"name":"Child Health and Evaluative Sciences, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avram","family":"Denburg","sequence":"additional","affiliation":[{"name":"Child Health and Evaluative Sciences, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Division of Hematology\/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[{"name":"Child Health and Evaluative Sciences, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Division of Hematology\/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"2025072914411160000_4.5.e001825.1","unstructured":"International Agency for Research on Cancer . Cancer Fact Sheets - All cancers: World Health Organization, 2019. Available: http:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/39-All-cancers-fact-sheet.pdf [Accessed 21 May 2019]."},{"key":"2025072914411160000_4.5.e001825.2","unstructured":"World Health Organization . Fact Sheets - Cancer: World Health Organization, 2018. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer [Accessed 21 May 2019]."},{"key":"2025072914411160000_4.5.e001825.3","unstructured":"National Cancer Institute . Cancer statistics, 2018. Available: https:\/\/www.cancer.gov\/about-cancer\/understanding\/statistics [Accessed 17 Oct 2018]."},{"key":"2025072914411160000_4.5.e001825.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70008-1"},{"key":"2025072914411160000_4.5.e001825.5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(18)30909-4","article-title":"Estimating the total incidence of global childhood cancer: a simulation-based analysis","volume":"20","author":"Ward","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025072914411160000_4.5.e001825.6","unstructured":"The global burden of childhood and adolescent cancer in 2017 . An analysis of the global burden of disease study 2017. Lancet Oncol 2019."},{"key":"2025072914411160000_4.5.e001825.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2012.01.006"},{"key":"2025072914411160000_4.5.e001825.8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(11)61337-8","article-title":"Progress towards millennium development goals 4 and 5 on maternal and child mortality: an updated systematic analysis","volume":"378","author":"Lozano","year":"2011","journal-title":"The Lancet"},{"key":"2025072914411160000_4.5.e001825.9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(19)30220-X","article-title":"Trends in cause-specific mortality among children aged 5\u201314 years from 2005 to 2016 in India, China, Brazil, and Mexico: an analysis of nationally representative mortality studies","volume":"393","author":"Fadel","year":"2019","journal-title":"The Lancet"},{"key":"2025072914411160000_4.5.e001825.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.0421"},{"key":"2025072914411160000_4.5.e001825.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6376"},{"key":"2025072914411160000_4.5.e001825.12","doi-asserted-by":"crossref","unstructured":"Eden T , Burns E , Freccero P , et al . Are essential medicines available, reliable and affordable in low-middle income countries? J Cancer Policy 2019;19.doi:10.1016\/j.jcpo.2018.12.001","DOI":"10.1016\/j.jcpo.2018.12.001"},{"key":"2025072914411160000_4.5.e001825.13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clon.2014.10.006","article-title":"Need for radiotherapy in low and middle income countries \u2013 the silent crisis continues","volume":"27","author":"Zubizarreta","year":"2015","journal-title":"Clin Oncol"},{"key":"2025072914411160000_4.5.e001825.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221292","article-title":"Political priority and pathways to scale-up of childhood cancer care in five nations","volume":"14","author":"Denburg","year":"2019","journal-title":"PLoS One"},{"key":"2025072914411160000_4.5.e001825.15","unstructured":"Knaul FM , Gralow JR , Atun R , et al . 1.ii myths and opportunities. North Andover, MA: Closing the Cancer Divide: An Equity Imperative Harvard University Press, 2012."},{"key":"2025072914411160000_4.5.e001825.16","first-page":"1","article-title":"Evidence from Ghana indicates that childhood cancer treatment in sub-Saharan Africa is very cost effective: a report from the childhood cancer 2030 network","volume":"4","author":"Renner","year":"2018","journal-title":"J Glob Oncol"},{"key":"2025072914411160000_4.5.e001825.17","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-301419"},{"key":"2025072914411160000_4.5.e001825.18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cncr.31022","article-title":"The cost and cost-effectiveness of childhood cancer treatment in El Salvador, central America: a report from the childhood cancer 2030 network","volume":"124","author":"Fuentes-Alabi","year":"2018","journal-title":"Cancer"},{"key":"2025072914411160000_4.5.e001825.19","first-page":"4033","article-title":"Treatment costs for pediatrics acute lymphoblastic leukemia; comparing clinical expenditures in developed and developing countries: a review article","volume":"4","author":"Hayati","year":"2016","journal-title":"Int J Pediatrics-Mashhad"},{"key":"2025072914411160000_4.5.e001825.20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-0912"},{"key":"2025072914411160000_4.5.e001825.21","unstructured":"Union for International Cancer Control . Cancer resolution, 2018. Available: https:\/\/www.uicc.org\/what-we-do\/advocacy\/global-commitment\/cancer-resolution [Accessed 25 Oct 2018]."},{"key":"2025072914411160000_4.5.e001825.22","unstructured":"World Health Organization . Global initiative for childhood cancer, 2018. Available: http:\/\/www.who.int\/cancer\/childhood-cancer\/en\/ [Accessed 17 Oct 2018]."},{"key":"2025072914411160000_4.5.e001825.23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20910"},{"key":"2025072914411160000_4.5.e001825.24","unstructured":"The World Bank . World bank country and lending groups: the world bank group, 2018. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups [Accessed 17 Oct 2018]."},{"key":"2025072914411160000_4.5.e001825.25","unstructured":"International Monetary Fund . Consumer price index (CpI), 2019. Available: http:\/\/data.imf.org [Accessed 1 Mar 2019]."},{"key":"2025072914411160000_4.5.e001825.26","unstructured":"World Health Organization . Health service delivery costs. WHO-CHOICE unit cost estimates for service delivery, 2019. Available: https:\/\/www.who.int\/choice\/cost-effectiveness\/inputs\/health_service\/en\/ [Accessed 1 Mar 2019]."},{"key":"2025072914411160000_4.5.e001825.27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23428"},{"key":"2025072914411160000_4.5.e001825.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002"},{"key":"2025072914411160000_4.5.e001825.29","doi-asserted-by":"publisher","DOI":"10.1097\/BLO.0b013e31805d85c4"},{"key":"2025072914411160000_4.5.e001825.30","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/cncr.32006","article-title":"The cost effectiveness of treating Burkitt lymphoma in Uganda","volume":"125","author":"Denburg","year":"2019","journal-title":"Cancer"},{"key":"2025072914411160000_4.5.e001825.31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.12122","article-title":"Improved outcome for children with non-high risk acute lymphoblastic leukaemia after using an all IC-BFM 2002-based protocol in Shanghai, China","volume":"160","author":"Gao","year":"2013","journal-title":"Br J Haematol"},{"key":"2025072914411160000_4.5.e001825.32","first-page":"549","article-title":"Cost-Effectiveness of consolidation treatments for acute myeloid leukemia in high-risk pediatric patients within the Colombian healthcare system","volume":"35","author":"Garcia","year":"2015","journal-title":"Biomedica"},{"key":"2025072914411160000_4.5.e001825.33","first-page":"103","article-title":"Financial burden of therapy in families with a child with acute lymphoblastic leukemia: report from North India","volume":"24","author":"Ghatak","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025072914411160000_4.5.e001825.34","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/10428190701784730","article-title":"Clinical outcome of children with newly diagnosed acute lymphoblastic leukemia treated in a single center in Shanghai, China","volume":"49","author":"LJ","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2025072914411160000_4.5.e001825.35","first-page":"407","article-title":"Cost-Utility of protocols of BFM-ALL and UK-ALL for treatment of children with acute lymphoblastic leukemia in Iran","volume":"47","author":"Hayati","year":"2018","journal-title":"Iranian Journal of Public Health"},{"key":"2025072914411160000_4.5.e001825.36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/pbc.23055","article-title":"Carboplatin-based chemotherapy and surgery: a cost effective treatment strategy for malignant extracranial germ cell tumours in the developing world","volume":"57","author":"Hendricks","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2025072914411160000_4.5.e001825.37","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10322"},{"key":"2025072914411160000_4.5.e001825.38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcpo.2015.10.002","article-title":"Cost of treatment for children with acute lymphoblastic leukemia in Bangladesh","volume":"6","author":"Islam","year":"2015","journal-title":"J Cancer Policy"},{"key":"2025072914411160000_4.5.e001825.39","doi-asserted-by":"crossref","unstructured":"Israels T , Paintsil V , Nyirenda D , et al . Improved outcome at end of treatment in the Collaborative Wilms tumour Africa project. Pediatr Blood Cancer 2018;65.doi:10.1002\/pbc.26945","DOI":"10.1002\/pbc.26945"},{"key":"2025072914411160000_4.5.e001825.40","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0218"},{"key":"2025072914411160000_4.5.e001825.41","first-page":"10","article-title":"Estimation of chemotherapy costs applying the full protocol of children with acute lymphoblastic leukemia or Hodgkin's lymphoma: case study","volume":"69","author":"Jasso-Gutierrez","year":"2012","journal-title":"Boletin Medico del Hospital Infantil de Mexico"},{"key":"2025072914411160000_4.5.e001825.42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/ijmpo.ijmpo_110_17","article-title":"Affordable and safe health care for all children: lessons learned from the use of PEG-asparaginase in a developing country","volume":"38","author":"Jayaraman","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2025072914411160000_4.5.e001825.43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3928\/01913913-20120710-04","article-title":"Direct costs for retinoblastoma treatment during the first year of comprehensive therapy in China","volume":"49","author":"Ji","year":"2012","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2025072914411160000_4.5.e001825.44","doi-asserted-by":"crossref","unstructured":"Kanyamuhunga A , Tuyisenge L , Stefan DC . Treating childhood cancer in Rwanda: the nephroblastoma example. Pan Afr Med J 2015;21.doi:10.11604\/pamj.2015.21.326.5912","DOI":"10.11604\/pamj.2015.21.326.5912"},{"key":"2025072914411160000_4.5.e001825.45","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22127"},{"key":"2025072914411160000_4.5.e001825.46","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21598"},{"key":"2025072914411160000_4.5.e001825.47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pbc.22042","article-title":"Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols","volume":"53","author":"Luo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2025072914411160000_4.5.e001825.48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01348.x"},{"key":"2025072914411160000_4.5.e001825.49","first-page":"1","article-title":"Cost of treating pediatric cancer at the Butaro cancer center of excellence in Rwanda","volume":"4","author":"Neal","year":"2018","journal-title":"J Glob Oncol"},{"key":"2025072914411160000_4.5.e001825.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.030"},{"key":"2025072914411160000_4.5.e001825.51","first-page":"285","article-title":"Out-Of-Pocket expenditures during hospitalization of young leukemia patients with state medical insurance in two Mexican hospitals","volume":"45","author":"Rocha-Garcia","year":"2003","journal-title":"Salud Publica De Mexico"},{"key":"2025072914411160000_4.5.e001825.52","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802663205"},{"key":"2025072914411160000_4.5.e001825.53","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22746"},{"key":"2025072914411160000_4.5.e001825.54","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-306206"},{"key":"2025072914411160000_4.5.e001825.55","first-page":"1","article-title":"Retinoblastoma in sub-Saharan Africa: case studies of the Republic of Cote d'Ivoire and the Democratic Republic of the Congo","volume":"4","author":"JJA","year":"2018","journal-title":"J Glob Oncol"},{"key":"2025072914411160000_4.5.e001825.56","unstructured":"Woods B , Revill P , Sculpher M , et al . Country-Level cost-effectiveness thresholds: initial estimates and the need for further research. Working papers. Centre for Health Economics, University of York, 2015: 109cherp."},{"key":"2025072914411160000_4.5.e001825.57","doi-asserted-by":"crossref","unstructured":"Stenberg K , Sweeny K , Axelson H , et al . Returns on Investment in the Continuum of Care for Reproductive, Maternal, Newborn, and Child Health. In: Black RE , Laxminarayan R , Temmerman M , et al , eds. Reproductive, maternal, newborn, and child health: disease control priorities, third edition, volume 2. Washington, DC: The International Bank for Reconstruction and Development \/ The World Bank (c) 2016 International Bank for Reconstruction and Development \/ The World Bank, 2016.","DOI":"10.1596\/978-1-4648-0348-2_ch16"},{"key":"2025072914411160000_4.5.e001825.58","doi-asserted-by":"crossref","unstructured":"Horton S , Levin C . Cost-Effectiveness of interventions for reproductive, maternal, neonatal, and child health in: black R, editor. reproductive, maternal, newborn, and child health: disease control priorities. 2. third ED. Washington, DC: The International Bank for Reconstruction and Development \/ The World Bank, 2016.","DOI":"10.1596\/978-1-4648-0348-2_ch17"},{"key":"2025072914411160000_4.5.e001825.59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182951","article-title":"Supplementary table 1. details of interventions included in figures 1, 2, 3 and 4, ordered by increasing cost per DALY averted. in ranking 93 health interventions for low- and middle-income countries by cost-effectiveness","volume":"12","author":"Horton","year":"2017","journal-title":"PloS one"},{"key":"2025072914411160000_4.5.e001825.60","unstructured":"Atun R , Bhakta N , Denburg A , et al . Lancet oncology Commission for sustainable care for children with cancer. Lancet Oncology In press."},{"key":"2025072914411160000_4.5.e001825.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.024"},{"key":"2025072914411160000_4.5.e001825.62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001656","article-title":"Pediatric oncology as the next global child health priority: the need for national childhood cancer strategies in low- and middle-income countries","volume":"11","author":"Gupta","year":"2014","journal-title":"PLoS Med"},{"key":"2025072914411160000_4.5.e001825.63","doi-asserted-by":"crossref","DOI":"10.1186\/1475-9276-7-4","article-title":"Priority setting in health care: lessons from the experiences of eight countries","volume":"7","author":"Sabik","year":"2008","journal-title":"Int J Equity Health"},{"key":"2025072914411160000_4.5.e001825.64","first-page":"1","article-title":"Costing methods applied to cancer","volume":"5","author":"Horton","year":"2019","journal-title":"J Glob Oncol"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2019-001825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T21:41:29Z","timestamp":1753825289000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2019-001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,10,31]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/bmjgh-2019-001825"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2019-001825","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}